Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).
Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Menter A; PSOLAR Steering Committee. Kimball AB, et al. Among authors: calabro s. Br J Dermatol. 2014 Jul;171(1):137-47. doi: 10.1111/bjd.13013. Epub 2014 Jul 16. Br J Dermatol. 2014. PMID: 24684204 Free PMC article.
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Chavers S, Naessens D, Sermon J, Krueger GG. Menter A, et al. Among authors: calabro s. J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1148-58. doi: 10.1111/jdv.13611. Epub 2016 Mar 30. J Eur Acad Dermatol Venereol. 2016. PMID: 27027388 Free PMC article.
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L. Kimball AB, et al. Among authors: calabro s. Br J Dermatol. 2018 Oct;179(4):984-986. doi: 10.1111/bjd.16737. Epub 2018 Jul 20. Br J Dermatol. 2018. PMID: 29747219 No abstract available.
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M. Gottlieb AB, et al. Among authors: calabro s. J Am Acad Dermatol. 2012 Oct;67(4):642-50. doi: 10.1016/j.jaad.2011.10.020. Epub 2011 Dec 9. J Am Acad Dermatol. 2012. PMID: 22153792 Clinical Trial.
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, Goyal K, Fakharzadeh S, Calabro S, Chevrier M, Langholff W, You Y, Leonardi CL. Kalb RE, et al. Among authors: calabro s. JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718. JAMA Dermatol. 2015. PMID: 25970800 Clinical Trial.
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y, Galindo C, Lee S, Lebwohl MG. Strober BE, et al. Among authors: calabro s. J Am Acad Dermatol. 2016 May;74(5):851-61.e4. doi: 10.1016/j.jaad.2015.12.017. Epub 2016 Feb 4. J Am Acad Dermatol. 2016. PMID: 26853180 Free article.
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee. Papp KA, et al. Among authors: calabro s. J Drugs Dermatol. 2012 Oct;11(10):1210-7. J Drugs Dermatol. 2012. PMID: 23134986
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G. Papp K, et al. Among authors: calabro s. J Am Acad Dermatol. 2015 Jan 9:S0190-9622(14)02102-1. doi: 10.1016/j.jaad.2014.10.025. Online ahead of print. J Am Acad Dermatol. 2015. PMID: 25582533
133 results